Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $13.8050 (3.68%) ($12.7800 - $13.8650) on Thu. Sep. 24, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.76% (three month average) | RSI | 53 | Latest Price | $13.8050(3.68%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.1% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(49%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.38% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-11%) UNG(-5%) IGOV(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.38% (StdDev 2.76%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $13.86 | 5 Day Moving Average | $13.8(0.04%) | 10 Day Moving Average | $13.75(0.4%) | 20 Day Moving Average | $13.86(-0.4%) | To recent high | -13.1% | To recent low | 7.2% | Market Cap | $3.565b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |